Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 28:10:1107.
doi: 10.3389/fonc.2020.01107. eCollection 2020.

Optimizing MR-Guided Radiotherapy for Breast Cancer Patients

Maureen L Groot Koerkamp  1 , Jeanine E Vasmel  1 , Nicola S Russell  2 , Simona F Shaitelman  3 , Carmel N Anandadas  4 , Adam Currey  5 , Danny Vesprini  6 , Brian M Keller  6 , Chiara De-Colle  7 , Kathy Han  8 , Lior Z Braunstein  9 , Faisal Mahmood  10   11 , Ebbe L Lorenzen  10 , Marielle E P Philippens  1 , Helena M Verkooijen  12 , Jan J W Lagendijk  1 , Antonetta C Houweling  1 , H J G Desiree van den Bongard  1 , Anna M Kirby  13
Affiliations
Review

Optimizing MR-Guided Radiotherapy for Breast Cancer Patients

Maureen L Groot Koerkamp et al. Front Oncol. .

Abstract

Current research in radiotherapy (RT) for breast cancer is evaluating neoadjuvant as opposed to adjuvant partial breast irradiation (PBI) with the aim of reducing the volume of breast tissue irradiated and therefore the risk of late treatment-related toxicity. The development of magnetic resonance (MR)-guided RT, including dedicated MR-guided RT systems [hybrid machines combining an MR scanner with a linear accelerator (MR-linac) or 60Co sources], could potentially reduce the irradiated volume even further by improving tumour visibility before and during each RT treatment. In this position paper, we discuss MR guidance in relation to each step of the breast RT planning and treatment pathway, focusing on the application of MR-guided RT to neoadjuvant PBI.

Keywords: MR-guided radiotherapy; MR-linac; breast cancer; hybrid machine; magnetic resonance imaging (MRI); neoadjuvant radiation therapy; partial breast irradiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Supine patient setup for MRI simulation. In this setup, a 5-degree inclined wedge is used. Height-adjustable coil bridges are used as support for the anterior receiver coil to prevent deformation of the body contour.
Figure 2
Figure 2
Patient and receiver coil positioning in prone position, including challenges in this position. The images show three different patients. (A) No space for the receiver coil on the back of the patient if the breast hangs freely without touching the scanner table; (B) the receiver coil fits above the patient while also the breast hangs freely; (C) when the receiver coil is fitted in the MRI bore above the patient, the breast touches the table top and is deformed. Light blue shapes represent the receiver coils (horizontal: receiver coil array; vertical: single flex coil). SNR, signal-to-noise ratio.
Figure 3
Figure 3
Imaging of a primary breast tumour on CT (A,D), (contrast-enhanced) MRI (B,E), and CBCT (C,F) scans indicating the difference in tumour visibility (inside the red circle) between these modalities in two different patients (A–C and D–F). (D–F) The marker inserted in the tumour medial in the left breast is observed as a void on MRI (indicated by the red circles).
Figure 4
Figure 4
Simulation of a single fraction neoadjuvant PBI treatment plan (ABLATIVE trial approach, 1 × 20 Gy to GTV) for the 1.5-T MR-linac. The calculated dose distribution shows the electron stream effect in air resulting in dose outside of the treatment field in both cranial and caudal directions. Scale is set to 100% reference dose = 20 Gy.
See this image and copyright information in PMC

References

    1. van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, et al. . 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. (2016). 17:1158–70. 10.1016/S1470-2045(16)30067-5 - DOI - PubMed
    1. Aalders KC, van Bommel ACM, van Dalen T, Sonke GS, van Diest PJ, Boersma LJ, et al. . Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer. (2016) 63:118–26. 10.1016/j.ejca.2016.05.010 - DOI - PubMed
    1. American Cancer Society Cancer Facts & Figures 2020. Atlanta: American Cancer Society; (2020). Available online at: https://www.cancer.org/research/cancer-facts-statistics.html
    1. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. . De-escalating and escalating treatments for early-stage breast cancer: the St. gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. (2017) 28:1700–12. 10.1093/annonc/mdx308 - DOI - PMC - PubMed
    1. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial):5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. (2017) 90:1048–60. 10.1016/S0140-6736(17)31145-5 - DOI - PMC - PubMed

LinkOut - more resources